BIOLOGÍA MOLECULAR Y CELULAR EN HEMOPATÍAS
Karolinska Institute
Estocolmo, SueciaKarolinska Institute-ko ikertzaileekin lankidetzan egindako argitalpenak (12)
2023
-
Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's Macroglobulinemia
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 14, pp. 2607-2616
-
Differences in the immunoglobulin gene repertoires of IgG versus IgA multiple myeloma allude to distinct immunopathogenetic trajectories
Frontiers in Oncology, Vol. 13
-
Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteria
Seminars in Hematology
-
Report of consensus panel 5 from the 11th international workshop on Waldenstrom's macroglobulinemia on COVID-19 prophylaxis and management
Seminars in Hematology
-
Report of consensus panel 7 from the 11th international workshop on Waldenström macroglobulinemia on priorities for novel clinical trials
Seminars in Hematology
2021
-
Validation of the EuroClonality-NGS DNA capture panel as an integrated genomic tool for lymphoproliferative disorders
Blood Advances, Vol. 5, Núm. 16, pp. 3188-3198
2020
-
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: The ASPEN study
Blood, Vol. 136, Núm. 18, pp. 2038-2050
2018
-
ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia - Update on methodological approaches and results interpretation
Leukemia, Vol. 32, Núm. 5, pp. 1070-1080
2016
-
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment
Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557
-
Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia
Blood, Vol. 128, Núm. 10, pp. 1321-1328
2015
-
American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma
Biology of Blood and Marrow Transplantation, Vol. 21, Núm. 12, pp. 2039-2051